• Home
  • Category: Medical Oncology

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

EORTC 22922/10925 was a randomized, phase 3 trial done across 46 radiation oncology departments from 13 countries. 15-year follow-up of 554 patients i...

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies. Elig...

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

DANUBE is an open-label, randomised, controlled, phase 3 trial in patients with untreated, unresectable, locally advanced or metastatic urothelial car...

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The study compared pembrolizumab plus axitinib and sunitinIB for advanced renal cell carcinoma. Median follow-up of 30.6 months showed continued clini...

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

PANORAMA 3 is an open-label, randomized, phase 2 study being done at 71 sites across 21 countries. Patients aged 18 years or older with relapsed or re...

Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study

Detecting microsatellite instability (MSI) in colorectal cancer is crucial for clinical decision-making. Universal MSI testing is recommended, but man...

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Combining an agonistic CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumor regression in mice and improves survival. The study w...

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Nadofaragene firadenovec is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium. 55...

Departments

Recent Posts